A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Tadalafil (ADCIRCA)

Tadalafil is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of: erectile dysfunction (ED) ( 1.1 ) the signs and symptoms of benign prostatic hyperplasia (BPH) ( 1.2 ) ED and the....

First FDA approval2003-11-26
Generic availableYes · 28 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$161.4M in CY2024 Part D spend628K claims · 192K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.104/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.104
Across all dosage forms in distribution.
Highest NADAC
$0.104
Range is tight.
Plans with PA
1057 / 329
Substantial PA friction across plans.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Tadalafil used for?

Tadalafil is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of: erectile dysfunction (ED) ( 1.1 ) the signs and symptoms of benign prostatic hyperplasia (BPH) ( 1.2 ) ED and the....

Is there a generic for Tadalafil?

Yes. 111 ANDAs filed at FDA, 28 generic manufacturers currently shipping.

How much does my plan pay for Tadalafil?

Across 329 Part D plans, Tadalafil averages $0.104/unit (NADAC). Lowest available: $0.104/unit. Highest in distribution: $0.104/unit.

Is Tadalafil on the FDA shortage list?

No. Tadalafil is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Phosphodiesterase 5 Inhibitor3 alternatives in D1
01
Avanafil
Phosphodiesterase 5 Inhibitor
$42.14Lowest NADAC
1Generic mfrs
CY24 Part D spend
Compare →
02
Sildenafil
Brand: Revatio
$0.053Lowest NADAC
25Generic mfrs
$66.0MCY24 Part D spend
Compare →
03
Vardenafil
Phosphodiesterase 5 Inhibitor
$2.23Lowest NADAC
5Generic mfrs
$642,093CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.